Aligos Therapeutics (NASDAQ:ALGS) Trading Up 4.2% – Should You Buy?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) shares shot up 4.2% on Tuesday . The stock traded as high as $4.37 and last traded at $4.25. Approximately 87,495 shares traded hands during mid-day trading, a decline of 72% from the average daily volume of 308,959 shares. The stock had previously closed at $4.08.

Analysts Set New Price Targets

Several equities analysts have recently commented on ALGS shares. Wall Street Zen raised shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, May 17th. Lake Street Capital initiated coverage on Aligos Therapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $45.00 price objective for the company. Weiss Ratings upgraded Aligos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a report on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Aligos Therapeutics Trading Up 4.2%

The stock’s 50-day moving average price is $5.48 and its 200-day moving average price is $6.64. The company has a market capitalization of $26.31 million, a P/E ratio of -0.49 and a beta of 2.26.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The business had revenue of $2.83 million during the quarter, compared to the consensus estimate of $0.25 million. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%. Sell-side analysts expect that Aligos Therapeutics, Inc. will post -7.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

Several institutional investors have recently made changes to their positions in ALGS. Woodline Partners LP acquired a new stake in shares of Aligos Therapeutics during the 1st quarter worth approximately $2,602,000. Marshall Wace LLP bought a new position in Aligos Therapeutics during the 4th quarter worth $2,504,000. Bank of America Corp DE grew its stake in Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after buying an additional 216,646 shares during the last quarter. Vanguard Group Inc. grew its stake in Aligos Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after buying an additional 31,913 shares during the last quarter. Finally, SummitTX Capital L.P. increased its position in Aligos Therapeutics by 6.7% in the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after buying an additional 9,375 shares during the period. 60.43% of the stock is owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.